Loading patent…
AssigneeYoshitomi Pharmaceutical Industries, Ltd.
InventorsTakeki Okumoto, Kenji Chiba, Yukio Hoshino, Hirotsugu Komatsu, Mariko Nagasawa, Hidekazu Aratani, Michio Terasawa, Minoru Moriwaki
Estimating the term…
An immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor, each containing a thienotriazolodiazepine compound wherein the 2-position of its diazepine ring is alkylated as an active ingredient, an immunosuppression method, an autoimmune disease treating method, an immunosuppression enhancing method and a cell adhesion inhibiting method, each of which comprising administering the compound, and uses of the compound for the production of an immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor.
A method for inhibiting cell adhesion, wherein said cell adhesion is caused by intercellular adhesion molecules, which comprises the step of administering to a subject in need of such inhibiting an effective amount of 4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)-ethyl)-6,9-dimethyl-6H-thieno 3,2-f!1,2,4!triazolo4,3-a!1,4!diazepine, an optical isomer thereof, or a pharmaceutically acceptable acid addition salt or hydrate thereof.
A method for inhibiting expression of intercellular adhesion molecules which comprises the step of administering to a subject in need of such inhibiting an effective amount of 4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)-ethyl)-6,9-dimethyl-6H-thieno3 ,2-f!1,2,4!triazolo4,3-a!1,4!diazepine, an optical isomer thereof, or a pharmaceutically acceptable acid addition salt or hydrate thereof.
A method for inhibiting at least one of the intercellular adhesion molecules LB.sub.4 or CD.sub.18, which comprises the step of administering to a subject in need of such inhibiting an effective amount of 4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)-ethyl)-6,9-dimethyl-6H-thieno3 ,2-f!1,2,4!triazolo4,3-a!1,4!diazepine, an optical isomer thereof, or a pharmaceutically acceptable acid addition salt or hydrate thereof.
Dependencies are inferred from the claim text.